Comparison of Treatment Goals for Moderate-to-Severe Psoriasis between Korean Dermatologists and the European Consensus Report
2
조회
0
다운로드
10
인용
0
참고문헌
키워드
초록
Background: The development of therapies for psoriasis hasled to the need for a new strategy to the treatment of patientswith moderate-to-severe psoriasis. New consensus guidelinesfor psoriasis treatment have been developed in somecountries, some of which have introduced treatment goals todetermine the timing of therapeutic regimens for psoriasis. Objective: To investigate the opinions held by Korean dermatologistswho specialize in psoriasis about treatmentgoals, and to compare these with the European consensus. Methods: Korean dermatologists who specialize in psoriasiswere asked 11 questions about defining the treatment goalsfor psoriasis. The questionnaire included questions about thefactors used to classify the severity of psoriasis, defining theinduction and maintenance phases of psoriasis treatment,defining treatment responses during the induction phase,and defining treatment responses during the maintenancephase. Results: The Korean consensus showed responsesthat were almost similar to the European consensus, evenwithout using the Delphi technique, which uses repeatedrounds of questions to reach a consensus. Only one responsethat related to psoriasis severity in the context of the qualityof patients’ lives differed from the European consensus. Conclusion: The concept of using treatment goals in the treatmentof moderate-to-severe psoriasis can be applied toKorean psoriasis patients. Since a tool for assessing the qualityof patients’ lives is not commonly used in Korea, the developmentof a simple, rapidly completed, and region-specifichealth-related quality of life assessment tool would enabletreatment goals to be used in routine clinical practice.
Abstract
Background: The development of therapies for psoriasis hasled to the need for a new strategy to the treatment of patientswith moderate-to-severe psoriasis. New consensus guidelinesfor psoriasis treatment have been developed in somecountries, some of which have introduced treatment goals todetermine the timing of therapeutic regimens for psoriasis. Objective: To investigate the opinions held by Korean dermatologistswho specialize in psoriasis about treatmentgoals, and to compare these with the European consensus. Methods: Korean dermatologists who specialize in psoriasiswere asked 11 questions about defining the treatment goalsfor psoriasis. The questionnaire included questions about thefactors used to classify the severity of psoriasis, defining theinduction and maintenance phases of psoriasis treatment,defining treatment responses during the induction phase,and defining treatment responses during the maintenancephase. Results: The Korean consensus showed responsesthat were almost similar to the European consensus, evenwithout using the Delphi technique, which uses repeatedrounds of questions to reach a consensus. Only one responsethat related to psoriasis severity in the context of the qualityof patients’ lives differed from the European consensus. Conclusion: The concept of using treatment goals in the treatmentof moderate-to-severe psoriasis can be applied toKorean psoriasis patients. Since a tool for assessing the qualityof patients’ lives is not commonly used in Korea, the developmentof a simple, rapidly completed, and region-specifichealth-related quality of life assessment tool would enabletreatment goals to be used in routine clinical practice.
참고문헌 (14)
- Nestle FO, "Psoriasis", N Engl J Med, 361, pp.496~509 (2009)
- Galadari I, "Psoriasis: a fresh look", Clin Dermatol, 23, pp.491~502 (2005)
- Parisi R, "Global epidemiology of psoriasis: a systematic review of incidence and prevalence", J Invest Dermatol, 133, pp.377~385 (2013)
- Hsu S, "National Psoriasis Foundation Medical Board. Consensus guidelines for the management of plaque psoriasis", Arch Dermatol, 148, pp.95~102 (2012)
- Pathirana D, "On the development of the European S3guidelines on the systemic treatment of psoriasis vulgaris:structure and challenges", J Eur Acad Dermatol Venereol, 24, pp.1458~1467 (2010)
- Ohtsuki M, "Biologics Review Committee of the Japanese Dermatological Association. Japanese guidance for use of biologics for psoriasis (the 2013 version)", J Dermatol, 40, pp.683~695 (2013)
- Smith CH, "British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009", Br J Dermatol, 161, pp.987~1019 (2009)
- Kragballe K, "Implementing best practice in psoriasis: a Nordic expert group consensus", Acta Derm Venereol, 94, pp.547~552 (2014)
- Mrowietz U, "Definition of treatment goals for moderate to severe psoriasis: a European consensus", Arch Dermatol Res, 303, pp.1~10 (2011)
- Finlay AY, "Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use", Clin Exp Dermatol, 19, pp.210~216 (1994)
- Finlay AY, "Dermatology life quality index (DLQI): a paradigm shift to patient-centered outcomes", J Invest Dermatol, 132, pp.2464~2465 (2012)
- Ashok Kumar Gupta, "Effectiveness of Conventional Drug Therapy of Plaque Psoriasis in the Context of Consensus Guidelines: A Prospective Observational Study in 150 Patients", Annals of Dermatology, 25(2), pp.156~162 (2013), 대한피부과학회
- 이영욱, "Impact of Psoriasis on Quality of Life: Relationship between Clinical Response to Therapy and Change in Health-related Quality of Life", Annals of Dermatology, 22(4), pp.389~396 (2010), 대한피부과학회
- Zweegers J, "Comparing treatment goals for psoriasis with treatment decisions in daily practice: results from a prospective cohort of patients with psoriasis treated with biologics: BioCAPTURE", Br J Dermatol, 171, pp.1091~1098 (2014)